Neumora Therapeutics (NMRA) Accounts Payables (2022 - 2026)

Neumora Therapeutics' Accounts Payables history runs 5 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 380.7% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (up 380.7% YoY), while the FY2025 annual figure was $3.4 million, up 2.18% from the prior year.
• Accounts Payables was $5.1 million for Q1 2026 at Neumora Therapeutics, up from $3.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.1 million in Q4 2022 to a low of $337000.0 in Q4 2023.
• Historically, Accounts Payables has averaged $2.7 million across 5 years, with a median of $1.9 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables tumbled 95.28% in 2023, then soared 881.31% in 2024.
• A 5-year view of Accounts Payables shows it stood at $7.1 million in 2022, then sank by 95.28% to $337000.0 in 2023, then jumped by 881.31% to $3.3 million in 2024, then climbed by 2.18% to $3.4 million in 2025, then surged by 49.66% to $5.1 million in 2026.
• The last three Accounts Payables figures came in at $5.1 million (Q1 2026), $3.4 million (Q4 2025), and $549000.0 (Q3 2025), per Business Quant data.